PDCD1 and skin squamous cell carcinoma: The next step will be to elucidate the role of anti-PD-1 in the adjuvant setting; two phase III clinical trials assessing adjuvant cemiplimab (NCT03969004) and adjuvant pembrolizumab (NCT03833167) following surgery and RT in locally advanced cSCC patients are currently ongoing.